Plasma Levels of Plasminogen Activator Inhibitor Type 1, P-Thromboglobulin, and Fibrinopeptide A Before, During, and After Treatment of Acute Myocardial Infarction With Alteplase

Plasma levels of plasminogen activator inhibitor type-1 (PAI1). p-thromboglobulin (pTG), and fibrinopeptide A (FPA) were followed over 24 hours in 30 patients treated with alteplase for acute myocardial infarction. Samples were taken at baseline (T Oh), after 90 minutes (under alteplase, no heparin, T 1.5h). after 120 minutes (under alteplase and heparin, T 2h), 30 minutes after thrombolytic therapy (T 3.5h), as well as 12 hours (T 12h) and 24 hours (T 24h) after baseline. PAI-1 antigen levels (55 f 9 ng/mL at T Oh, mean f SEM) decreased to 35 ? 5 (T 1.5h) and 40 ? 6 (T 2h) ng/mL under alteplase, before increasing to 84 f 22 (T 3.5h). 130 ? 30 (T 12h). and 64 f 7 (T24h) ng/mL after therapy, P < .001. A high baseline PAL1 activity (18 f 3 ng/mL) decreased t o 2.0 f 0.4 (T 1.5h) and 1.7 * 0.2 (T 2h) under alteplase and increased to 32 f 5 (T 12h) and 19 * 3 (T 24h) ng/mL after therapy (P < .0001). pTG levels (339 ? 105 ng/mL at T Oh) decreased to 203 f 48 (T 2h), 154 f 51 (T 3.5h). 187 f 40 (T 12h), and